Home / Insurance / Does Aetna Cover Wegovy? Insurance Guide 2026
MC
Reviewed by Marcus Chen Updated February 20, 2026

Does Aetna Cover Wegovy? Insurance Guide 2026

Bold opening

In 2026, Wegovy remains one of the most effective FDA-approved medications for chronic weight management and obesity-related conditions. However, navigating insurance coverage—particularly with providers like Aetna—can be complex. As a glucagon-like peptide-1 (GLP-1) receptor agonist, Wegovy (semaglutide) is prescribed for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. Many patients wonder: Does Aetna cover Wegovy? The answer depends on your specific plan, medical necessity, and adherence to prior authorization requirements. This guide provides evidence-based insights into Aetna’s coverage policies for Wegovy, cost considerations, and steps to secure approval or appeal denials.

Does Aetna Cover Wegovy for Diabetes?

Aetna’s coverage of Wegovy for diabetes management is nuanced, as Wegovy is not FDA-approved for diabetes treatment—its counterpart, Ozempic (semaglutide), is. However, Aetna may cover Wegovy under certain circumstances if a patient has both obesity and type 2 diabetes, particularly if other GLP-1 agonists (e.g., Ozempic, Trulicity) have failed or caused intolerable side effects. Clinical guidelines from the American Diabetes Association (ADA) support the use of GLP-1 agonists for glycemic control and weight loss in diabetic patients, which may influence Aetna’s decision.

To qualify, prescribers must document:

  1. A diagnosis of type 2 diabetes with inadequate glycemic control (HbA1c >7%).
  2. Failure or intolerance to preferred diabetes medications (e.g., metformin, SGLT2 inhibitors).
  3. Concurrent obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities (e.g., hypertension, dyslipidemia).

Aetna’s medical policy often requires step therapy, meaning patients must try and fail other diabetes medications before Wegovy is approved. Coverage is more likely under commercial plans than Medicare or Medicaid, as these programs have stricter criteria. Always verify with Aetna’s formulary or your plan’s pharmacy benefits manager (PBM) for the most current policies.

Does Aetna Cover Wegovy for Weight Loss?

Aetna does cover Wegovy for chronic weight management, but approval is contingent on strict clinical criteria aligned with FDA labeling and Aetna’s medical policy. Wegovy is indicated for adults with:

  • A BMI ≥30 (obesity), or
  • A BMI ≥27 (overweight) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, obstructive sleep apnea).

Aetna’s coverage policy requires documentation of:

  1. Medical necessity: A physician must confirm the patient’s BMI and comorbidities.
  2. Lifestyle interventions: Patients must have attempted and failed a supervised diet and exercise program for at least 6 months.
  3. Exclusion of secondary causes: Conditions like hypothyroidism or Cushing’s syndrome must be ruled out.

Coverage is typically limited to 12–24 months, as Wegovy is intended for long-term use. Aetna may require reauthorization after the initial approval period, with evidence of weight loss progress (e.g., ≥5% total body weight loss at 3 months). Commercial plans are more likely to cover Wegovy than high-deductible or self-funded plans, so review your specific policy details.

How Much Does Wegovy Cost With Aetna?

The out-of-pocket cost of Wegovy with Aetna varies widely based on your plan’s formulary tier, deductible, and copay structure. Without insurance, Wegovy retails for approximately $1,300–$1,600 per month, but Aetna’s negotiated rates can reduce this significantly.

Key cost factors include:

  1. Formulary tier: Wegovy is often placed on Tier 3 or Tier 4 (preferred or non-preferred specialty drugs), resulting in copays of $50–$150 per month or coinsurance of 20–50% of the drug’s cost.
  2. Deductibles: If your plan has a high deductible (e.g., $1,500–$3,000), you may pay the full negotiated price until the deductible is met.
  3. Prior authorization: Approval can lower costs, but denials may leave you responsible for the full price.
  4. Manufacturer savings: Novo Nordisk offers a Wegovy savings card for commercially insured patients, reducing copays to $0–$25 per month for up to 24 months. However, this is not available for Medicare or Medicaid beneficiaries.

To estimate your cost, use Aetna’s member portal or call customer service with your prescription details. For example, a patient with a $50 copay and the savings card might pay $0–$25/month, while someone with a high-deductible plan could pay $1,000+ until the deductible is satisfied.

Wegovy Prior Authorization for Aetna

Aetna requires prior authorization (PA) for Wegovy to ensure medical necessity and cost-effectiveness. The PA process involves submitting clinical documentation to Aetna’s pharmacy benefits manager (PBM), often CVS Caremark or Express Scripts. Here’s what prescribers must include:

  1. Patient demographics: Name, age, weight, height, and BMI.
  2. Diagnosis codes: ICD-10 codes for obesity (E66.9) or overweight with comorbidities (e.g., E66.01 for obesity with alveolar hypoventilation, I10 for hypertension).
  3. Failed interventions: Documentation of a 6-month supervised diet and exercise program with no significant weight loss (e.g., <5% total body weight).
  4. Comorbidities: List of weight-related conditions (e.g., type 2 diabetes, sleep apnea, cardiovascular disease).
  5. Prescriber attestation: Confirmation that Wegovy is medically necessary and that the patient is a candidate for long-term therapy.

Aetna typically reviews PA requests within 3–10 business days. If approved, coverage is usually granted for 3–6 months, with reauthorization required thereafter. Denials often occur due to incomplete documentation or failure to meet step therapy requirements. Prescribers can appeal denials by submitting additional clinical evidence or requesting a peer-to-peer review with an Aetna medical director.

How to Get Aetna to Cover Wegovy

Securing Aetna’s coverage for Wegovy requires a strategic, evidence-based approach. Follow these steps to improve your chances of approval:

  1. Verify eligibility: Confirm your BMI (≥30 or ≥27 with comorbidities) and ensure you’ve tried a 6-month diet/exercise program with no success. Document this with progress notes or a physician’s letter.
  2. Choose the right prescriber: A bariatric specialist, endocrinologist, or obesity medicine physician is more likely to succeed with PA requests than a general practitioner. These specialists understand Aetna’s criteria and can provide robust clinical justification.
  3. Submit a thorough PA request: Work with your prescriber to include:
    • Detailed medical history (e.g., failed weight loss attempts, comorbidities).
    • Lab results (e.g., HbA1c, lipid panel, blood pressure readings).
    • A treatment plan outlining Wegovy’s role in your long-term weight management.
  4. Leverage step therapy: If Aetna requires trying other medications first (e.g., phentermine, Qsymia), comply with these requirements and document failures or intolerances.
  5. Use the savings card: If approved, enroll in Novo Nordisk’s Wegovy savings program to reduce copays to $0–$25/month for up to 24 months.
  6. Appeal if denied: If Aetna denies coverage, request a peer-to-peer review or submit an appeal with additional evidence (e.g., letters of medical necessity from specialists).

Pro tip: Some Aetna plans offer weight management programs (e.g., Aetna’s “Healthy Lifestyles” program) that may provide additional support or incentives for Wegovy users.

What to Do If Aetna Denies Wegovy

If Aetna denies coverage for Wegovy, don’t lose hope—denials are often overturned with the right approach. Here’s how to appeal:

  1. Understand the denial reason: Aetna’s denial letter will specify why Wegovy was rejected (e.g., lack of medical necessity, failure to meet step therapy, incomplete documentation). Common reasons include:
    • BMI not meeting criteria.
    • Insufficient evidence of failed lifestyle interventions.
    • Missing lab results or progress notes.
  2. Request a peer-to-peer review: Ask your prescriber to speak directly with an Aetna medical director. This conversation can clarify clinical nuances and address Aetna’s concerns in real time.
  3. Submit an appeal: Gather additional evidence to support your case, such as:
    • Letters of medical necessity from specialists (e.g., endocrinologist, cardiologist).
    • Progress notes documenting failed weight loss attempts.
    • Lab results showing weight-related comorbidities (e.g., elevated HbA1c, hypertension).
    • Published guidelines (e.g., ADA, Obesity Medicine Association) supporting Wegovy’s use.
  4. Escalate if necessary: If the appeal is denied, request an external review by an independent third party. This is your right under the Affordable Care Act (ACA) for most commercial plans.
  5. Explore alternatives: If appeals fail, consider other GLP-1 agonists (e.g., Saxenda, Zepbound) or weight loss programs covered by Aetna (see next section).

Time is critical: Appeals must typically be filed within 60–180 days of the denial, depending on your plan. Work closely with your prescriber to meet deadlines and strengthen your case.

Aetna Alternatives If Wegovy Is Not Covered

If Aetna denies Wegovy or the cost is prohibitive, several alternatives may be covered or more affordable:

  1. Other GLP-1 agonists:
    • Saxenda (liraglutide): FDA-approved for obesity, often covered by Aetna with PA. Similar efficacy to Wegovy but requires daily injections.
    • Zepbound (tirzepatide): A dual GIP/GLP-1 agonist approved for obesity (BMI ≥30 or ≥27 with comorbidities). Aetna may cover it if Wegovy is denied, but it’s newer and may require step therapy.
    • Ozempic (semaglutide): FDA-approved for type 2 diabetes but often prescribed off-label for weight loss. Aetna may cover it if you have diabetes, but it’s not indicated for obesity alone.
  2. Non-GLP-1 medications:
    • Qsymia (phentermine/topiramate): Aetna often covers this with PA. It’s effective but has more side effects (e.g., insomnia, dry mouth).
    • Contrave (naltrexone/bupropion): Another Aetna-covered option, but less effective than GLP-1 agonists.
  3. Lifestyle programs:
    • Aetna’s Healthy Lifestyles program offers coaching, nutrition counseling, and discounts on weight loss programs (e.g., Weight Watchers, Noom).
    • Bariatric surgery: Aetna covers procedures like gastric bypass or sleeve gastrectomy for patients with BMI ≥40 or ≥35 with comorbidities. Requires extensive documentation and PA.
  4. Manufacturer assistance:
    • Novo Nordisk’s patient assistance program provides Wegovy at no cost for uninsured or underinsured patients who meet income criteria.
    • Mark Cuban Cost Plus Drug Company offers semaglutide (the generic for Wegovy/Ozempic) at a lower cost (~$300/month), though it’s not FDA-approved for weight loss.

Discuss these options with your prescriber to find the best fit for your health and budget.

Frequently Asked Questions

Does Aetna cover Wegovy for weight loss?

Yes, Aetna covers Wegovy for weight loss if you meet FDA criteria (BMI ≥30 or ≥27 with comorbidities) and have documented failed lifestyle interventions. Coverage requires prior authorization, and approval is not guaranteed. Commercial plans are more likely to cover Wegovy than Medicare or Medicaid.

How much is the Wegovy copay with Aetna?

The copay for Wegovy with Aetna varies by plan but typically ranges from $50–$150 per month for Tier 3/4 drugs. With Novo Nordisk’s savings card, eligible patients may pay $0–$25/month for up to 24 months. High-deductible plans may require paying the full cost (~$1,300/month) until the deductible is met.

Can I appeal if Aetna denies Wegovy?

Yes, you can appeal Aetna’s denial of Wegovy. Start by requesting a **peer-to-peer